On December 28, 2018, Horizon Pharma plc sold the rights to RAVICTI and AMMONAPS (known as BUPHENYL in the United States) outside of North America and Japan to Medical Need Europe AB, part of the Immedica Group, based in Stockholm, Sweden, for $35 million. Horizon Pharma previously distributed RAVICTI and AMMONAPS through a commercial partner in Europe and other non-U.S. markets. Horizon Pharma will retain rights to RAVICTI and AMMONAPS/BUPHENYL in North America and Japan. Horizon Pharma will no longer recognize revenue from RAVICTI and AMMONAPS sales outside of North America and Japan.